

# Drugs and Devices Division

## Drug Submission Status

Report for September 2019

## Complete Streamlined Multiple-Source

## Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Zoledronic Acid	Zometa Concentrate	zoledronic acid	4mg/5mL	IV solution	02482525
Pharmascience Inc.	PMS-Fingolimod	Gilenya	fingolimod HCl	0.5mg	capsule	02469782
Apotex Inc.	Apo-Dabigatran	Pradaxa	dabigatran etexilate mesylate	75mg	capsule	02468891
Natco Pharma (Canada) Inc.	Nat-Gefitinib	Iressa	gefitinib	250mg	FC tablet	02491796